KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) FCF Margin (2016 - 2025)

Historic FCF Margin for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to 2.47%.

  • Emergent BioSolutions' FCF Margin fell 528100.0% to 2.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.18%, marking a year-over-year decrease of 148200.0%. This contributed to the annual value of 3.43% for FY2024, which is 280100.0% up from last year.
  • As of Q3 2025, Emergent BioSolutions' FCF Margin stood at 2.47%, which was down 528100.0% from 73.46% recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' FCF Margin peaked at 85.8% during Q2 2024, and registered a low of 121.18% during Q1 2023.
  • Over the past 5 years, Emergent BioSolutions' median FCF Margin value was 13.45% (recorded in 2021), while the average stood at 7.04%.
  • Per our database at Business Quant, Emergent BioSolutions' FCF Margin crashed by -983800bps in 2023 and then soared by 1233600bps in 2024.
  • Emergent BioSolutions' FCF Margin (Quarter) stood at 38.52% in 2021, then dropped by -27bps to 28.1% in 2022, then tumbled by -73bps to 7.48% in 2023, then plummeted by -660bps to 41.91% in 2024, then soared by 94bps to 2.47% in 2025.
  • Its last three reported values are 2.47% in Q3 2025, 73.46% for Q2 2025, and 6.66% during Q1 2025.